| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mitral Valve Insufficiency | 8 | 2023 | 98 | 3.280 |
Why?
|
| Heart Failure | 22 | 2023 | 965 | 3.050 |
Why?
|
| Stroke Volume | 13 | 2020 | 345 | 1.470 |
Why?
|
| Mitral Valve | 6 | 2023 | 126 | 1.460 |
Why?
|
| Hypertrophy, Left Ventricular | 11 | 2012 | 124 | 1.270 |
Why?
|
| Ventricular Function, Left | 9 | 2016 | 284 | 1.260 |
Why?
|
| Heart Ventricles | 12 | 2009 | 267 | 0.830 |
Why?
|
| Echocardiography, Doppler | 9 | 2020 | 133 | 0.720 |
Why?
|
| Ventricular Remodeling | 6 | 2023 | 95 | 0.680 |
Why?
|
| Adrenergic beta-Antagonists | 5 | 2007 | 152 | 0.660 |
Why?
|
| Adenosine | 4 | 2004 | 79 | 0.640 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2017 | 170 | 0.590 |
Why?
|
| Hemodynamics | 4 | 2016 | 252 | 0.590 |
Why?
|
| Myocardial Contraction | 10 | 2012 | 88 | 0.580 |
Why?
|
| Norepinephrine | 3 | 2004 | 106 | 0.550 |
Why?
|
| Blood Pressure | 8 | 2014 | 535 | 0.540 |
Why?
|
| Double Outlet Right Ventricle | 1 | 2016 | 4 | 0.500 |
Why?
|
| Hypertension | 4 | 2012 | 616 | 0.480 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2016 | 15 | 0.470 |
Why?
|
| Models, Cardiovascular | 1 | 2016 | 83 | 0.470 |
Why?
|
| Hemofiltration | 1 | 2014 | 17 | 0.430 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 68 | 0.420 |
Why?
|
| Echocardiography | 11 | 2017 | 513 | 0.400 |
Why?
|
| Renal Dialysis | 1 | 2014 | 191 | 0.390 |
Why?
|
| Lectins, C-Type | 1 | 2013 | 80 | 0.390 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 135 | 0.380 |
Why?
|
| Myocardium | 7 | 2004 | 302 | 0.380 |
Why?
|
| Outpatients | 1 | 2013 | 143 | 0.370 |
Why?
|
| Diastole | 7 | 2017 | 90 | 0.370 |
Why?
|
| Systole | 9 | 2012 | 109 | 0.360 |
Why?
|
| Male | 38 | 2016 | 31281 | 0.360 |
Why?
|
| Humans | 44 | 2023 | 65632 | 0.340 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2007 | 139 | 0.340 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 1567 | 0.330 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2012 | 624 | 0.320 |
Why?
|
| Aged | 25 | 2016 | 15084 | 0.320 |
Why?
|
| Heart | 4 | 2000 | 298 | 0.320 |
Why?
|
| Decision Making | 1 | 2014 | 429 | 0.320 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 526 | 0.310 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2004 | 58 | 0.300 |
Why?
|
| Mitral Valve Annuloplasty | 2 | 2020 | 17 | 0.290 |
Why?
|
| Female | 31 | 2016 | 34294 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 733 | 0.290 |
Why?
|
| Rats | 9 | 2012 | 1996 | 0.280 |
Why?
|
| Massachusetts | 11 | 2016 | 2154 | 0.270 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2018 | 186 | 0.270 |
Why?
|
| Coronary Disease | 2 | 2003 | 246 | 0.270 |
Why?
|
| Chronic Disease | 3 | 2017 | 744 | 0.260 |
Why?
|
| Prognosis | 6 | 2014 | 1791 | 0.260 |
Why?
|
| Receptors, Purinergic P1 | 2 | 2004 | 12 | 0.250 |
Why?
|
| Survival Analysis | 2 | 2020 | 579 | 0.250 |
Why?
|
| Pacemaker, Artificial | 2 | 2013 | 50 | 0.240 |
Why?
|
| Ventricular Pressure | 4 | 2007 | 31 | 0.230 |
Why?
|
| Angina, Unstable | 1 | 2005 | 56 | 0.220 |
Why?
|
| Middle Aged | 21 | 2016 | 18431 | 0.220 |
Why?
|
| Aortic Valve | 3 | 2002 | 181 | 0.220 |
Why?
|
| Cardiomyopathies | 2 | 2009 | 137 | 0.220 |
Why?
|
| Presynaptic Terminals | 1 | 2004 | 38 | 0.210 |
Why?
|
| Propanolamines | 1 | 2004 | 10 | 0.210 |
Why?
|
| Carbazoles | 1 | 2004 | 13 | 0.210 |
Why?
|
| Tetrazoles | 1 | 2004 | 22 | 0.210 |
Why?
|
| Metoprolol | 1 | 2004 | 18 | 0.210 |
Why?
|
| Shock, Cardiogenic | 1 | 2005 | 108 | 0.210 |
Why?
|
| Cardiomegaly | 2 | 2001 | 37 | 0.210 |
Why?
|
| Life Style | 1 | 2006 | 324 | 0.200 |
Why?
|
| Benzimidazoles | 1 | 2004 | 55 | 0.200 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2023 | 20 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 808 | 0.190 |
Why?
|
| Myocardial Infarction | 3 | 2005 | 921 | 0.190 |
Why?
|
| Antihypertensive Agents | 1 | 2004 | 183 | 0.190 |
Why?
|
| Dexfenfluramine | 1 | 2002 | 5 | 0.180 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2002 | 13 | 0.180 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 2 | 0.180 |
Why?
|
| Adrenergic Antagonists | 1 | 2001 | 3 | 0.170 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2018 | 40 | 0.170 |
Why?
|
| Hodgkin Disease | 1 | 2001 | 54 | 0.170 |
Why?
|
| Receptors, Adrenergic | 1 | 2000 | 8 | 0.160 |
Why?
|
| Heart Valve Diseases | 1 | 2001 | 93 | 0.160 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2000 | 25 | 0.160 |
Why?
|
| Heart Failure, Diastolic | 2 | 2010 | 9 | 0.150 |
Why?
|
| Disease Progression | 4 | 2012 | 1225 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2020 | 5818 | 0.150 |
Why?
|
| Dipyridamole | 1 | 1998 | 17 | 0.140 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1998 | 20 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2013 | 2496 | 0.140 |
Why?
|
| Comorbidity | 5 | 2016 | 1120 | 0.140 |
Why?
|
| Protein Kinase C | 1 | 1998 | 102 | 0.140 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 72 | 0.130 |
Why?
|
| Coronary Vessels | 2 | 1999 | 125 | 0.130 |
Why?
|
| Coronary Artery Bypass | 2 | 2018 | 292 | 0.130 |
Why?
|
| Recurrence | 2 | 2018 | 664 | 0.120 |
Why?
|
| Survival Rate | 3 | 2016 | 847 | 0.120 |
Why?
|
| In Vitro Techniques | 3 | 2004 | 491 | 0.120 |
Why?
|
| Aged, 80 and over | 9 | 2007 | 5653 | 0.120 |
Why?
|
| Atrial Function, Left | 1 | 2016 | 32 | 0.120 |
Why?
|
| Cardiac Catheterization | 2 | 2018 | 293 | 0.120 |
Why?
|
| Mitoxantrone | 1 | 2016 | 16 | 0.120 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2016 | 27 | 0.120 |
Why?
|
| Diuretics | 2 | 2007 | 58 | 0.120 |
Why?
|
| Health Services Administration | 1 | 2015 | 4 | 0.120 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2018 | 171 | 0.110 |
Why?
|
| Heart Function Tests | 1 | 1995 | 16 | 0.110 |
Why?
|
| Animals | 10 | 2012 | 21450 | 0.110 |
Why?
|
| Health Services | 1 | 2015 | 80 | 0.110 |
Why?
|
| Cause of Death | 2 | 2013 | 221 | 0.110 |
Why?
|
| Thoracic Surgery | 1 | 2015 | 80 | 0.110 |
Why?
|
| Chi-Square Distribution | 3 | 2010 | 413 | 0.100 |
Why?
|
| Uncertainty | 1 | 2014 | 40 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2016 | 486 | 0.100 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2013 | 5 | 0.100 |
Why?
|
| Cardiology | 1 | 2015 | 170 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 309 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 193 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 741 | 0.100 |
Why?
|
| Obesity | 1 | 2002 | 1277 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 1994 | 121 | 0.100 |
Why?
|
| Biomarkers | 2 | 2013 | 1487 | 0.100 |
Why?
|
| Heart Failure, Systolic | 2 | 2010 | 16 | 0.100 |
Why?
|
| Purinergic P1 Receptor Agonists | 2 | 2004 | 6 | 0.100 |
Why?
|
| Hepatic Veins | 1 | 2013 | 13 | 0.100 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2013 | 6 | 0.100 |
Why?
|
| ROC Curve | 1 | 2013 | 292 | 0.090 |
Why?
|
| Ventricular Function | 2 | 2007 | 22 | 0.090 |
Why?
|
| Hospitalization | 3 | 2010 | 1403 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 1995 | 273 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2013 | 96 | 0.090 |
Why?
|
| Patient Participation | 1 | 2014 | 239 | 0.090 |
Why?
|
| Prevalence | 4 | 2010 | 1453 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 1172 | 0.090 |
Why?
|
| Stress, Mechanical | 2 | 2009 | 118 | 0.090 |
Why?
|
| Perfusion | 3 | 2001 | 76 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2009 | 6946 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2015 | 533 | 0.080 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 273 | 0.080 |
Why?
|
| Peripheral Arterial Disease | 1 | 2013 | 165 | 0.080 |
Why?
|
| Ultrasonography | 3 | 2009 | 491 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1116 | 0.080 |
Why?
|
| Acute Disease | 2 | 2010 | 663 | 0.080 |
Why?
|
| Hospital Mortality | 3 | 2005 | 879 | 0.080 |
Why?
|
| Organ Size | 2 | 2001 | 174 | 0.080 |
Why?
|
| Pericardium | 2 | 2000 | 35 | 0.080 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2009 | 50 | 0.070 |
Why?
|
| Heart Valve Prosthesis | 2 | 2002 | 107 | 0.070 |
Why?
|
| Age Factors | 2 | 2007 | 1592 | 0.070 |
Why?
|
| Body Weight | 2 | 2001 | 377 | 0.070 |
Why?
|
| Coronary Circulation | 2 | 2001 | 55 | 0.070 |
Why?
|
| Logistic Models | 2 | 2010 | 1273 | 0.060 |
Why?
|
| Inpatients | 1 | 2010 | 322 | 0.060 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2007 | 10 | 0.060 |
Why?
|
| Risk Factors | 4 | 2016 | 5466 | 0.060 |
Why?
|
| Reference Values | 2 | 2007 | 328 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2007 | 2319 | 0.060 |
Why?
|
| Heart Rate | 3 | 2007 | 334 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2013 | 3328 | 0.060 |
Why?
|
| Electrocardiography | 2 | 2003 | 555 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 188 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2007 | 210 | 0.060 |
Why?
|
| Aging | 2 | 2003 | 775 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 606 | 0.060 |
Why?
|
| Age Distribution | 1 | 2006 | 262 | 0.060 |
Why?
|
| Necrosis | 2 | 2003 | 148 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 992 | 0.050 |
Why?
|
| Urban Population | 1 | 2005 | 201 | 0.050 |
Why?
|
| Coronary Angiography | 3 | 2009 | 212 | 0.050 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2004 | 117 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2007 | 1026 | 0.050 |
Why?
|
| Electric Countershock | 1 | 2004 | 109 | 0.050 |
Why?
|
| Incidence | 4 | 2016 | 1432 | 0.050 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2003 | 9 | 0.050 |
Why?
|
| Creatine Kinase | 1 | 2003 | 42 | 0.050 |
Why?
|
| Rhabdomyolysis | 1 | 2003 | 23 | 0.050 |
Why?
|
| Viridans Streptococci | 1 | 2002 | 5 | 0.050 |
Why?
|
| Troponin I | 1 | 2003 | 36 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 858 | 0.050 |
Why?
|
| Syndrome | 1 | 2003 | 180 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 130 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 489 | 0.050 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2002 | 42 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 462 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 2002 | 87 | 0.040 |
Why?
|
| Abscess | 1 | 2002 | 79 | 0.040 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2001 | 4 | 0.040 |
Why?
|
| Inosine | 1 | 2001 | 5 | 0.040 |
Why?
|
| Isoproterenol | 1 | 2001 | 37 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2001 | 34 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2001 | 208 | 0.040 |
Why?
|
| Caffeine | 1 | 2001 | 46 | 0.040 |
Why?
|
| Myocardial Reperfusion | 1 | 2000 | 23 | 0.040 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2000 | 23 | 0.040 |
Why?
|
| Endocardium | 1 | 1999 | 14 | 0.040 |
Why?
|
| Survival | 1 | 1998 | 11 | 0.040 |
Why?
|
| Registries | 1 | 2002 | 933 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 1998 | 391 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 1715 | 0.030 |
Why?
|
| Calcium | 1 | 2001 | 584 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2009 | 1144 | 0.030 |
Why?
|
| Heart Diseases | 1 | 1999 | 223 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2001 | 2189 | 0.030 |
Why?
|
| United States | 3 | 2009 | 8165 | 0.030 |
Why?
|
| Syncope | 1 | 1996 | 42 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 60 | 0.030 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2015 | 7 | 0.030 |
Why?
|
| Bioprosthesis | 1 | 1996 | 38 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2004 | 884 | 0.030 |
Why?
|
| Time Factors | 3 | 2009 | 3776 | 0.030 |
Why?
|
| Cardiac Output | 1 | 1994 | 29 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 318 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1994 | 116 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2010 | 755 | 0.030 |
Why?
|
| Aorta | 1 | 1994 | 108 | 0.020 |
Why?
|
| Lung | 1 | 1998 | 969 | 0.020 |
Why?
|
| Dogs | 1 | 1994 | 317 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 79 | 0.020 |
Why?
|
| Device Removal | 1 | 2013 | 64 | 0.020 |
Why?
|
| Adult | 5 | 2009 | 17507 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 644 | 0.020 |
Why?
|
| Cardiotonic Agents | 1 | 2009 | 54 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2009 | 295 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 1660 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2009 | 210 | 0.020 |
Why?
|
| Midazolam | 1 | 2004 | 12 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2009 | 475 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2004 | 40 | 0.010 |
Why?
|
| Anesthetics, Intravenous | 1 | 2004 | 25 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 160 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 213 | 0.010 |
Why?
|
| Fentanyl | 1 | 2004 | 67 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 2113 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 2639 | 0.010 |
Why?
|
| Demography | 1 | 2002 | 178 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2002 | 170 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2002 | 204 | 0.010 |
Why?
|
| Survivors | 1 | 2002 | 187 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 1580 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2000 | 58 | 0.010 |
Why?
|
| Disease Management | 1 | 2002 | 235 | 0.010 |
Why?
|
| Hospitals | 1 | 2002 | 398 | 0.010 |
Why?
|
| Myocardial Revascularization | 1 | 1999 | 78 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1999 | 105 | 0.010 |
Why?
|
| Observer Variation | 1 | 1999 | 216 | 0.010 |
Why?
|
| Tilt-Table Test | 1 | 1996 | 11 | 0.010 |
Why?
|
| Mechanoreceptors | 1 | 1996 | 13 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2003 | 2729 | 0.010 |
Why?
|
| Aortic Valve Stenosis | 1 | 1996 | 190 | 0.010 |
Why?
|